Aim:

Explor Target Antitumor Ther

ETAT

Exploration of Targeted Anti-tumor Therapy

2692-3114

Open Exploration Publishing

10.37349/etat.2024.00204

1002204

Original Article

Efficacy of metformin and electrical pulses in breast cancer MDA-MB-231 cells

https://orcid.org/0000-0002-0240-3108

Sahu

Praveen

Conceptualization Data curation Formal analysis Validation Visualization Writing—original draft Writing—review & editing ¹

https://orcid.org/0000-0001-9690-479X

Camarillo

Ignacio G.

Supervision Methodology Writing—review & editing ² ³

https://orcid.org/0000-0003-1817-9646

Sundararajan

Raji

Conceptualization Supervision Validation Writing—review & editing ¹ ^* Cerchia

Laura

Academic Editor Institute of Experimental Endocrinology and Oncology “G. Salvatore”-National Research Council (IEOS-CNR), Italy

¹School of Engineering Technology, Purdue University, West Lafayette, IN 47907, USA ²Department of Biological Sciences, Purdue University, West Lafayette, IN 47907, USA ³Purdue University Center for Cancer Research, Purdue University, West Lafayette, IN 47907, USA

^*Correspondence: Raji Sundararajan, School of Engineering Technology, Purdue University, Knoy 187, 401 North Grant Street, West Lafayette, IN 47907, USA. raji@purdue.edu

2024

19 02 2024

5 1 54 73 19 08 2023 30 10 2023

This is an Open Access article licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Aim:

Triple-negative breast cancer (TNBC) is a very aggressive subset of breast cancer, with limited treatment options, due to the lack of three commonly targeted receptors, which merits the need for novel treatments for TNBC. Towards this need, the use of metformin (Met), the most widely used type-2 diabetes drug worldwide, was explored as a repurposed anticancer agent. Cancer being a metabolic disease, the modulation of two crucial metabolites, glucose, and reactive oxygen species (ROS), is studied in MDA-MB-231 TNBC cells, using Met in the presence of electrical pulses (EP) to enhance the drug efficacy.

Methods:

MDA-MB-231, human TNBC cells were treated with Met in the presence of EP, with various concentrations Met of 1 mmol/L, 2.5 mmol/L, 5 mmol/L, and 10 mmol/L. EP of 500 V/cm, 800 V/cm, and 1,000 V/cm (with a pulse width of 100 µs at 1 s intervals) were applied to TNBC and the impact of these two treatments was studied. Various assays, including cell viability, microscopic inspection, glucose, ROS, and wound healing assay, were performed to characterize the response of the cells to the combination treatment.

Results:

Combining 1,000 V/cm with 5 mmol/L Met yielded cell viability as low as 42.6% at 24 h. The glucose level was reduced by 5.60-fold and the ROS levels were increased by 9.56-fold compared to the control, leading to apoptotic cell death.

Conclusions:

The results indicate the enhanced anticancer effect of Met in the presence of electric pulses. The cell growth is inhibited by suppressing glucose levels and elevated ROS. This shows a synergistic interplay between electroporation, Met, glucose, and ROS metabolic alterations. The results show promises for combinational therapy in TNBC patients.

Metformin triple-negative breast cancer MDA-MB-231 cells electroporation glucose reactive oxygen species cell migration wound healing assay

Introduction

Triple-negative breast cancer (TNBC) is a very aggressive subtype of breast cancer with limited treatment options [1–3]. The National Breast Cancer Coalition (NBCC) estimated more than 300,000 invasive breast cancer cases in women for 2023 [4]. Various advancements have been made in screening [5–7] and treatment methodologies, but cancer survival at the metastatic stage has not declined [8–12]. Around 15–20% of these breast cancer cases belong to the TNBC category [13]. Breast cancer gene 1 (BRCA1) and BRCA2 are well-known mutations responsible for approximately half of the hereditary breast cancer and belong to the class of high-penetrance breast cancer susceptible genes [14–16]. TNBC is a BRCA1-related breast cancer phenotype [17]. TNBC are more aggressive phenotype with a high proliferation rate [18], and an overall 5-year relative survival rate of only 77%, while characterized by the lack of estrogen receptors (ERs), progesterone receptors (PRs), and human epidermal growth factor receptor 2 (HER2) [19, 20].

In TNBC, approximately 30 somatic mutation genes are significantly differentially expressed compared to non-TNBC [21]. These mutations are associated with tumor progression, stimulate cell proliferation, and promote cell survival via metabolite cell signaling pathways such as insulin-like growth factors (IGFs) signaling pathway [22], notch signaling [23], the nuclear factor-kappa B (NF-κB) signaling [24] and phosphoinositide 3 kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) signaling pathway [25], and mitogen-activated protein kinase (MAPK) signaling pathway [26, 27]. So, targeting the metabolic pathways involving metabolites presents a potential strategy for treating TNBC patients.

TNBC has a clinically high recurrence rate of 40%, issues like poor prognosis, and development of resistance to chemotherapy [28]. Due to the lack of canonical molecular targets in TNBC, treatment options are limited to conventional chemotherapy drugs [29, 30]. The lack of effective treatments motivated us to find an alternative combination of drug therapy. Towards this, the study explored the repurposing metformin (Met), the most administered type-2 diabetes drug, as an anticancer agent.

Met is a widely used antidiabetic drug [31] that is readily available worldwide and it is inexpensive [32]. It was first synthesized in the 1920s, and its potential antidiabetic properties were recognized in the 1950s [33]. It has also garnered attention for its possible benefits in cancer, polycystic ovary syndrome, and cardiovascular diseases [34, 35]. Its pharmacodynamic effects are through action on hepatic glucose production, peripheral glucose uptake, and insulin sensitivity [36]. It lowers the glucose released into the bloodstream by inhibiting gluconeogenesis [37, 38]. It promotes glucose transporter type 4 (GLUT4) translocation to the cell membrane, facilitating glucose uptake from the bloodstream into the cells [39, 40]. This action improves glucose utilization by peripheral tissues, lowering glucose levels. Met also has several other beneficial effects beyond its glucose-lowering actions [41]. It activates adenosine monophosphate (AMP)-activated protein kinase (AMPK), a cellular energy sensor that regulates various metabolic processes [42].

Met also exhibits antiproliferative and anti-inflammatory effects [43, 44], which may affect cancer prevention [45] and treatment [46, 47]. Prior studies show it can inhibit cell growth, induce cell cycle arrest, and promote apoptosis (programmed cell death) in cancer cells [48]. These effects are mediated through multiple pathways, including inhibition of mTOR signaling and modulation of AMPK activity [49, 50]. As seen earlier in TNBC, aberrant activation of mTOR signaling has been observed, leading to increased cell proliferation and survival. So, Met could target the mTOR pathway, and if the drug uptake is enhanced in the presence of electrical pulses (EP), it can lead to a more effective treatment for TNBC.

To enhance the intracellular Met concentrations, EP was utilized. This technique, known as electroporation, involves opening membrane pores that increase drug uptake when a combination of field intensity and sufficient pulse duration are applied [51–53]. The rate of pore density is given by Equation 1 [54], as shown below:

dNdt= α × e(VmVeq)2 (1 - N0NeqVm )

Here, α is a constant that depends on the properties of the cell membrane, V_eq is the voltage at which pores are created, V_m is the transmembrane potential, and N (t, θ) is pore density, θ is a tuning parameter that affects the relationship between N_eq and V_m. N_eq is the equilibrium pore density for a given voltage V_m, where N₀ is the port density for V_m = 0 mV, and e is the base of the natural exponential (e = 2.71).

Electroporation-mediated chemotherapy, known as electrochemotherapy (ECT), has been extensively used in the European Union (EU) for treating cancer patients refractive to standard treatments. An extensive review by Joshi et al. [55] shows the successful implementation of ECT for various applications. Electroporation can minimize drug concentration and side effects on the surrounding tissues by improving drug efficacy [56]. Prior studies suggest that electroporation techniques can be effectively combined with various drugs to improve therapeutic efficacy [57–61]. This research examined the efficacy of a combination of Met with EP using various assays. The experimental design flow and the scope of the study are depicted in Figure 1.

Figure 1

Illustration of the experimental design flow and the scope of the research work. Double-sided arrow: pulse width; ROS: reactive oxygen species

Materials and methods TNBC cell line

MDA-MB-231 cell line (HTB-26^TM, American Type Culture Collection^®, USA) [62, 63] was used, which was originally derived from a 51-year-old white American woman with metastatic breast cancer [64]. MDA-MB-231 cells are spindle-like in shape with a mean diameter of 18–20 µm [65], as shown in Figure 2A and B. They were grown in the Dulbecco’s Modified Eagle Media (DMEM, 11965084, Thermo Fisher, USA) containing 10% fetal bovine serum (‎FBS, A5256801, Thermo Fisher, USA) and 1% penicillin-streptomycin (PS, 15070063, Thermo Fisher, USA) [66] to a final concentration of 10⁶ cells/mL.

Figure 2

Characterization of MDA-MB-231 cell line. (A) Microscopic image (10×); (B) the Gaussian distribution for the cell diameter (mean: 18 µm) of the untreated MDA-MB-231 cells. Avg: average

Met drug

Met, approved by the Food and Drug Administration (FDA) [67], belongs to the biguanide class with two methyl functional groups (-C=NH-NH₂) (Figure 3) [68–71]. It is an antidiabetic drug that shows antihyperglycemic activity (the ability of a substance to lower blood sugar levels) [72]. It is available as Met hydrochloride (1,1-dimethyl biguanide hydrochloride, C₄H₁₂ClN₅) from Sigma Aldrich^® [73], a pharmaceutical reference standard. Its molecular weight is 165.62 g/moL, and its solubility is 200 mg/mL in water [74]. A long-term (10-year) study by the diabetes prevention program research group determines that Met is safe and well tolerated [75]. The concentrations for dose optimization and further studies on the MDA-MB-231 cell line used are 1 mmol/L, 2.5 mmol/L, 5 mmol/L, and 10 mmol/L.

Figure 3

Chemical composition and structure of Met hydrochloride [76]

Electroporation

A BTX-ECM 830^® electroporator (Genetronics Inc. San Diego, USA) [77] was used to apply eight unipolar square pulses of 500 V/cm, 800 V/cm, and 1,000 V/cm, each with 100 µs pulse width for 1 s intervals. For electroporation, the cuvette having a 4 mm gap between the electrodes was filled with 600 µL of MDA-MB-231 cell suspension at 10⁶ cells/mL concentration adjusted to varying Met concentrations. The cuvette was inserted in the chamber, and the desired pulsing was applied. Following electroporation, cells were incubated in 96-well plates for various assays.

Cell viability assay

Real-time-Glo™ MT cell viability assay (G9711, Promega, USA) was used, which provides viability without damaging the cells with a bio-luminescent signal output [78]. The treated samples were incubated in 96-well plates. Each well contains 20 µL (20,000 cells per well) of treated sample and 55 µL of cell media. MT cell viability substrate and nanoLuc enzyme were added in the ratio 1,000:4 and 25 µL was added to each well at t = 0 h. Here, the MT cell viability substrate reduces to form nanoLuc substrate after diffusing into cells. The nanoLuc substrate exiting the cell is rapidly used by nanoLuc luciferase in the media. The substrate is reduced only by metabolically active cells. Thus, the luminescence value indicates the number of live cells represented by Equation 2 (RLU means relative luminescence units), as shown below:

Viability=Treated sample RLU valueControl sample RLU value × 100%

Microscopic cell inspection

Microscopic images assisted in establishing a visual correlation of the chemical assay with the morphological change and effects of drugs on cancer cells [79]. The sample treatment includes control, 1,000 V/cm, 5 mmol/L Met, and 1,000 V/cm + 5 mmol/L Met. After treatments under these conditions, 100 µL (100,000 cells per well) were seeded in a 12-well plate. After 24 h of treatment, a microscope (M150^®, AmScope, USA) was used to capture cell morphology transformations and mark any visible changes. The microscope was set to a 10× zoom to capture a more extensive field area. The acquired images were then analyzed, allowing to make inferences related to parameters such as cell morphology and co-localization.

Glucose assay

Glucose Uptake-Glo™ assay (J1341, Promega, USA) is a homogeneous metabolite detection assay that quantifies the rate at which the glucose uptake transpires inside the cancer cell [80]. The sample treatment includes control, 1,000 V/cm, 5 mmol/L Met, and 1,000 V/cm + 5 mmol/L Met. After treatment, 20 µL (20,000 cells per well) was transferred to a 96-well plate, and 80 µL of cell culture media (DMEM) was added. Next, 50 µL of a prepared 5 mmol/L solution of 2-deoxy-D-glucose (2DG) was added to each well, followed by a gentle mix for 10 min before incubating the sample. After an incubation period of 23 h, the stop buffer (25 µL) was added to each well, followed by 25 µL of neutralization buffer, and gently mixed. Subsequently, 100 µL of 2-deoxyglucose-6-phosphate (2DG6P) detection reagent was added and briefly shaken. The 2DG6P detection reagent was prepared 1 h in advance to minimize the assay background. The 96-well plate was then incubated at room temperature for another 30 min. Finally, the RLU were recorded using Synergy HTX multi-mode microplate reader (SLXATS, BioTek Instruments, USA) at 24 h with a 0.5 s integration time. The luminescence values were normalized with respect to the control.

ROS assay

ROS-Glo™ H₂O₂ assay (G882B, Promega, USA) was used to detect hydrogen peroxide (H₂O₂) in the sample directly, using a simple two-reagent protocol [81]. The sample treatment includes control, 1,000 V/cm, 5 mmol/L Met, and 1,000 V/cm + 5 mmol/L Met. After the treatment, cells were seeded in a 96-well plate at a desired density of 20,000 cells per well. An additional 60 µL of the medium was introduced to each well, making the final volume 80 µL. The cells were then placed in an incubator at 37°C CO₂ incubator for 18 h. Next, the H₂O₂ substrate dilution buffer thawing was carried out gently and kept on ice. The H₂O₂ substrate solution was prepared by diluting the 10 mmol/L H₂O₂ substrate to 125 µmol/L in the H₂O₂ substrate dilution buffer, ensuring optimal mixing. Enough H₂O₂ substrate solution was prepared for all samples. At 18 h, 20 µL of the prepared H₂O₂ substrate solution was added to each well. This resulted in a final well volume of 100 µL and a final H₂O₂ substrate concentration of 25 µmol/L. The plate was incubated for the next 6 h. Following this, 100 µL of ROS-Glo™ detection solution was added per well. The plate was incubated at room temperature (22°–25°C) for 20 min, and the luminescence values were recorded using Synergy HTX multi-mode microplate reader (SLXATS, BioTek Instruments, USA) in RLU. The luminescence values were normalized with respect to the control for analysis.

Wound healing assay

A wound healing assay was used to study the cell migration [82] of MDA-MB-231 cells under the influence of Met and electric pulse. The sample treatment includes control, 5 mmol/L Met, and 1,000 V/cm + 5 mmol/L Met. The culture-insert 2-well from Ibidi^® was used to create a defined cell-free gap of 500 µm in width [83]. The 10 mm culture dish was sterilized, and the culture-insert 2-well was inserted, creating two individual wells separated by a central divider. After treatment, 10 µL (10⁶ cells/mL) of cells were seeded to either side of the well. Then, the cells were allowed to grow for around 24 h inside the incubator (37°C, 5% CO₂, and 85% relative humidity).

The culture insert was removed after 90–95% confluency, creating a highly reproducible cell-free gap or “wound” between 2 wells, as shown in step 2 (Gap-Creation). Ultimately, it was expected that the cells on the sides to close the gap by growing and migrating. EVOS-FLTM digital microscope (AMEFC4300, Invitrogen™, USA) was used to capture images and measure the initial gap (t = 0 h). Then, the cells were incubated, and after 24 h incubation, another image was taken to capture cell migration.

ImageJ (version 1.53i), an open-source image analysis software by the National Institutes of Health (NIH), was utilized to quantify the extent of wound closure by measuring the area of the cell-free gap [84] at t = 0 h and t = 24 h. This allowed for the quantitative measurement and assessment of the migratory capabilities of the MDA-MB-231 cells under the influence of Met and electric pulse.

Statistical analysis

Repeated measure analysis of variance (ANOVA) was used to study the statistical significance of the assays, including cell viability, glucose, and ROS assay. Tukey’s test for multiple comparisons [85] was conducted after ANOVA. The significance level “P” was set to 0.05 to determine whether the difference between the means of any two-sample treatment is statistically significant. Also, after calculating the honestly significant difference (HSD) or the critical value (CV), alphabets (“A”, “B”, etc.) were assigned to all treatments. The Tukey’s HSD formula is given by Equation 3 [86], as shown below:

HSD= q × MSEn

Here, q is the CV derived from the studentized range distribution, MSE is the residual mean square from ANOVA, and n is the number of observations in each group. The standard q-score Tukey’s table was used to obtain the q-value corresponding to the specific number of treatments (k), degree of freedom (Df) within treatments, and n = 3 (each of the sample treatments was performed in triplicate). Here, the same alphabets for the treatments indicate that they are not significantly (ns) different, i.e., the difference between treatments was less than that of HSD, whereas different alphabets (P < 0.05) indicate they differ significantly (s). The statistical analysis was done using R-studio. All the values are represented as mean ± standard error (n = 3).

Results Dose curve

The dose curve at 24 h is shown in Figure 4. Here control is normalized to 100%. At 1 mmol/L, cell viability is 97.2% (slightly reduced compared to control), and it is 89.27% at 2.5 mmol/L. It declined to 78.3% at 5 mmol/L and 70% at 10 mmol/L. With the doubling of the drug dose from 5 mmol/L to 10 mmol/L, the reduction in viability is only 8.31%. This illustrates the saturation of the drug doses, and 5 mmol/L was chosen as the optimum dose for further experiments.

Figure 4

Met dosage curve for MDA-MB-231 cells at 24 h. The same letters indicate ns difference between the treatments, whereas different letters indicate a significant difference (^* P < 0.05). w.r.t.: with respect to

Tukey’s test indicates the same letter “A”, for control, 1 mmol/L, and 2.5 mmol/L, indicating that their viabilities are not statistically different (ns). The viabilities at both 5 mmol/L and 10 mmol/L are statistically different from the first three samples but not with each other. Thus, both are represented by the letter “B”. The summarizes Tukey’s test multiple comparisons between the samples in the Met dosage curve for MDA-MB-231 cells at 24 h is shown in Table 1.

Table 1

Summary of Tukey’s multiple comparisons for Met dose-curve in MDA-MB-231 cells at 24 h

Tukey’s multiple comparisons	Mean difference	95% CI of difference	Above HSD	Summary	Adjusted P value
Control vs. 1 mmol/L	2.8	–6.04 to 11.64	No	ns	0.8306
1 mmol/L vs. 2.5 mmol/L	7.93	–0.91 to 16.77	No	ns	0.0845
2.5 mmol/L vs. 5 mmol/L	10.97	2.12 to 19.81	Yes	*	0.0147
5 mmol/L vs. 10 mmol/L	8.31	–0.53 to 17.15	No	ns	0.068

^* P < 0.05. CI: confidence interval

Electrical parameter optimization

The viabilities of the MDA-MB-231 cells with EP only and EP + 5 mmol/L conditions are shown in Figure 5A. The control is normalized to 100%. Under EP-only conditions, at 500 V/cm, the cell viability is 89.53% and 84.97% for 800 V/cm. The cell viability reduces as we increase the electric field. It is as low as 72.90% at 1,000 V/cm.

Figure 5

Cell viability assay on MDA-MB-231 at different EP conditions (500 V/cm, 800 V/cm, 1,000 V/cm, 100 µs, 1 s interval). (A) Viability percentage for EP only and EP + 5 mmol/L Met. The same letters indicate ns difference between the treatments, whereas different letters indicate a significant difference (^*** P < 0.001); (B) the heatmap plot depicting the statistical difference in cell viability observed between EP only and EP + 5 mmol/L Met counterpart. w.r.t.: with respect to

Further, Tukey’s test indicates ns difference was observed for 500 V/cm and 800 V/cm, and both were represented by the letter “B”. The viability at 1,000 V/cm (represented by the letter “C”) significantly differs from all other sample treatments.

Likewise, the cell viability for 500 V/cm and 800 V/cm with 5 mmol/L is 87.53% and 84.97%, respectively. It is a minor reduction of 2.56% in viability compared to a 60% increment in the electric field magnitude. However, 1,000 V/cm with 5 mmol/L Met shows a significant decrease in viability to 42.60%.

Based on Tukey’s test (Table 2), 500 V/cm and 800 V/cm with 5 mmol/L Met were not statistically significant, and both were represented by the same letter “B”. The difference in cell viability between 1,000 V/cm with 5 mmol/L is significantly different and represented by the same letter “D”.

Table 2

Summary of Tukey’s test for Met treatment with and without EP on MDA-MB-231

Sample treatment	Above HSD	Summary	P value
500 V/cm vs. 500 V/cm + 5 mmol/L Met	No	ns	0.549472
800 V/cm vs. 800 V/cm + 5 mmol/L Met	No	ns	0.277932
1,000 V/cm vs. 1,000 V/cm + 5 mmol/L Met	Yes	***	0.000441

^*** P < 0.001

The heatmap comparing the EP only and EP + 5 mmol/L Met groups with color code representing the standard error of the difference between both groups is shown in Figure 5B. A maximum was observed impact at 1,000 V/cm on viability with 5 mmol/L Met compared to the 1,000 V/cm counterpart.

Microscopic cell inspection

The microscopic images for control, 1,000 V/cm, 5 mmol/L Met, and 1,000 V/cm + 5 mmol/L Met after 24 h of treatment are shown in Figure 6. In the case of control, cells appeared confluent and exhibited a spindle-like shape (characteristic of untreated MDA-MB-231 cells). At 1,000 V/cm, cell confluency was slightly lower compared to the control, with morphological changes induced by the electric pulses [87]. The 5 mmol/L Met sample exhibits a much lower cell confluence than the control, suggesting growth inhibition. It has a combination of live spindle-like cells and dead cell debris, indicating a mixed population of viable and non-viable cells.

Figure 6

Microscopic image inspection of MDA-MB-231 cells at 24 h for control, 1,000 V/cm, 5 mmol/L Met and 1,000 V/cm + 5 mmol/L Met

Further, at 1,000 V/cm + 5 mmol/L Met, the presence of sizeable dead cell debris suggests an increased cytotoxic effect compared to the 5 mmol/L Met treatment counterpart. Thus, the combination of 1,000 V/cm with 5 mmol/L Met shows an enhanced cytotoxic effect.

Glucose assay

The results of the glucose assay for control, 1,000 V/cm, 5 mmol/L Met, and 1,000 V/cm + 5 mmol/L Met after 24 h of treatment are shown in Figure 7. The glucose levels are measured in RLU. The glucose level for the control sample was 2,253.78 RLU. At 1,000 V/cm, it was 1,919.75 RLU indicating a 14.82 % decrease in glucose level compared to control. For 5 mmol/L Met, the glucose levels were substantially reduced to 66.72% to 750 RLU compared to the control. Next, the combination of 1,000 V/cm with 5 mmol/L Met resulted in a glucose level of 400 RLU (5.6 times lower than the control), indicating a drastic reduction in glucose.

Figure 7

Glucose assay for various treatments on MDA-MB-231 cells after 24 h of treatment. The same letters indicate ns difference between the treatments, whereas different letters indicate a significant difference (^*** P < 0.001; ^**** P < 0.0001)

Tukey’s multiple comparisons test for glucose assay (Table 3) indicates no statistical significance between control and 1,000 V/cm hence represented by the same letter “A”. The 1,000 V/cm + 5 mmol/L Met is statistically different (1.9 times lower) compared to the 5 mmol/L Met counterpart and represented by the letters “C” and “B”, respectively.

Table 3

Summary of Tukey’s multiple comparisons test for glucose assay in MDA-MB-231 at 24 h

Tukey’s multiple comparisons	Mean difference	95% CI of difference	Above HSD	Summary	Adjusted P value
Control vs. 1,000 V/cm	154	–18.71 to 326.8	No	ns	0.0816
1,000 V/cm vs. 5 mmol/L Met	1,350	1,177 to 1,522	Yes	****	< 0.0001
5 mmol/L Met vs. 1,000 V/cm + 5 mmol/L	450	277.3 to 622.7	Yes	***	0.0001

^*** P < 0.001; ^**** P < 0.0001

ROS assay

The result of the ROS assay for control, 1,000 V/cm, 5 mmol/L Met, and 1,000 V/cm + 5 mmol/L Met after 24 h of treatment is shown in Figure 8. The H₂O₂ levels are represented as RLU × 100. The control exhibited a ROS level of 914.22 RLU. For 1,000 V/cm, a 2.2-fold increase in ROS production was observed compared to the control. In the case of 5 mmol/L Met, ROS levels increment by 5.6-fold compared to the control. Further, for 1,000 V/cm + 5 mmol/L Met, the ROS levels exponentially increase to 9.6-fold with respect to the control, indicating synergy.

Figure 8

ROS assay for various treatments in MDA-MB-231 cells at 24 h. The same letters indicate ns difference between the treatments, whereas different letters indicate a significant difference (^**** P < 0.0001)

Tukey’s multiple comparison tests (Table 4) provide statistical insights into the differences in ROS levels among the different treatments. The control, 1,000 V/cm, 5 mmol/L Met, and 1,000 V/cm + 5 mmol/L Met are statistically different from each other (P value) and are represented by the letters “A”, “B”, “C”, and “D”, respectively.

Table 4

Summary of Tukey’s multiple comparisons test for ROS assay in MDA-MB-231 at 24 h

Tukey’s multiple comparisons	Mean difference	95% CI of difference	Above HSD	Summary	Adjusted P value
Control vs. 1,000 V/cm	–1,120	–1,488 to –752	Yes	****	< 0.0001
1,000 V/cm vs. 5 mmol/L Met	–3,120	–3,489 to –2,752	Yes	****	< 0.0001
5 mmol/L Met vs. 1,000 V/cm + 5 mmol/L	–3,611	–3,979 to –3,243	Yes	****	< 0.0001

^**** P < 0.0001

Wound healing assay

The microscopic images of wound healing assay inspection for control, 5 mmol/L Met, and 1,000 V/cm + 5 mmol/L Met at t = 0 h and t = 24 h are shown in Figure 9. The images at t = 0 h in Figure 9A were taken after the IbidiTM culture-insert 2-well was removed to see a cell-free gap of 500 µm in each sample. After incubation, the images at t = 24 h show that the control specimens proliferate without any inhibition, almost filling the gap. It shows the unrestricted migration of MDA-MB-231 cells. The 5 mmol/L Met treated sample inhibits cell migration and exhibits reduced migration compared to the control. Further, 1,000 V/cm + 5 mmol/L Met showed a more significant reduction in migration than the 5 mmol/L Met and control.

Figure 9

Wound healing assay in MDA-MB-231 cells at t = 0 h and t = 24 h for control, 5 mmol/L Met, 1,000 V/cm + 5mmol/L. (A) Microscopic image; (B) cell-free area (mm²) quantified using ImageJ

The cell-free area (in mm²) at t = 0 h and t = 24 h obtained from the ImageJ analysis is shown in Figure 9B. At t = 0 h, all the sample treatments (control, 5 mmol/L Met, 1,000 V/cm + 5 mmol/L Met) exhibited similar cell-free areas of 0.778 mm², 0.800 mm², and 0.820 mm², respectively. However, at t = 24 h, a notable divergence in the control group displayed a reduced cell-free area of 0.175 mm², indicating substantial migration and wound closure. In contrast, the 5 mmol/L Met group showed a moderately reduced cell-free area of 0.426 mm², suggesting a potential impairment in cell migration and wound closure. The 1,000 V/cm + 5 mmol/L Met group exhibited the largest cell-free area of 0.753 mm², signifying a pronounced inhibition of cell migration.

Discussion

Met enters cells through a process called transporter-mediated uptake. The primary transporter responsible for Met uptake is the organic cation transporter (OCT), which is expressed on the cell membrane (Figure 10) [88]. Prior studies have shown that EP can increase the uptake of external molecules up to 1,000 times (using bleomycin) through transient permeabilization of the cell membrane [89, 90] and by increasing the expression of transporters like OCT [91, 92]. This suggests a greater drug uptake for the combined treatment. Also, it is a favorable outcome for repurposing Met in the presence of EP as an anticancer agent for TNBC patients.

Figure 10

Illustration of the overview of the plausible mechanism of action for Met in the presence of electric pulses. It shows the effective entering of Met into the cell via the OCT and additional pores created by EP (at 1,000 V/cm). Met promotes the conversion of ATP to adenosine diphosphate (ADP) and AMP, thereby lowering mitochondrial energy production. Met’s impact on gluconeogenesis is highlighted by showing the inhibition of converting pyruvate to glucose. By impeding this process, Met contributes to decreased glucose levels and elevated ROS levels, creating an overall energy stress situation within the cell, ultimately leading to cell death. mGPD: mitochondrial glycerol-3-phosphate dehydrogenase; NAD⁺: depleted nicotinamide adenine dinucleotide

The microscopic inspection of cells also corroborates the antiproliferative effects of combined treatment. Here, the cell confluency and deviation from the characteristic spindle-like shape were used to conclude the impact of different treatments on untreated MBA-MB-231 cells. For instance, cell confluency measures how much of the surface of a culture dish is covered by cells [93]. It is an indicator of cell growth and proliferation, and for 1,000 V/cm + 5 mmol/L Met, a more pronounced reduction in cell confluency indicates that cells are dying or not dividing as rapidly. Similarly, when MBA-MB-231 cells die, they lose their spindle-like shape, indicating cell death or cycle arrest [94]. As seen in the case of 1,000 V/cm + 5 mmol/L Met, the observed sizable circular dead cell debris, suggesting enhanced cytotoxic effects of Met in the presence of EP (1,000 V/cm + 5 mmol/L Met), inducing cell cycle arrest.

Further, wound healing assay used for chemotaxis assessment (the migration of cells under the influence of a drug) [95] also indicates the same reduction in cell proliferation. It measures cell migration by creating a wound in a monolayer of cells and measuring how quickly the wound closes. The cell migration is directly correlated to the metastatic potential of cancer cells [96]. A faster wound closure rate indicates that the cells are migrating and proliferating more rapidly. In contrast, inhibition by decreased wound closure into the scratched area indicates the treatment’s capability to hinder the invasive potential of TNBC cells [97]. The results indicated that the combined treatment by Met in the presence of electric pulses (1,000 V/cm + 5 mmol/L Met) significantly impairs cell migration and inhibits wound closure. It is a positive outcome, as reduced cell migration is directly associated with decreased metastatic potential in cancer cells.

The working mechanisms of Met in cancer are complicated, and exploring various techniques to comprehend the pathways is still an ongoing task [98]. In general, TNBC cells display altered glucose metabolism by overexpressed glucose transporters [99] and exhibit dysregulation in glucose uptake by relying heavily on glucose for energy production (glycolysis) [100, 101]. The glucose assay results showed a 5.6-fold reduction in glucose levels for combined treatment (1,000 V/cm + 5 mmol/L Met) compared to the control. It suggests modulation in glucose metabolic pathways leading to low adenosine triphosphate (ATP) energy formation and enhanced cell death [102].

Glucose metabolic pathways are vital for maintaining cellular energy homeostasis [103]. Among the key players in these pathways are GLUT2, which facilitates glucose transport into cells, and glucokinase (GCK), catalyzing the initial step of glycolysis [104]. Phosphofructokinase 1 (PFK1) is a central glycolysis regulator, while pyruvate kinase M2 (PKM2) catalyzes the final glycolysis step, leading to pyruvate generation [105]. Furthermore, oxidative phosphorylation proteins (OXPHOS) are responsible for generating ATP from nicotinamide adenine dinucleotide (NADH) and flavin adenine dinucleotide (FADH2) in the electron transport chain (ETC) [106]. Next, glucose-6-phosphate dehydrogenase (G6PD) initiates the pentose phosphate pathway, while glucose-6-phosphatase (G6PC) catalyzes the initial step of gluconeogenesis [107]. These pathways are crucial for producing energy (ATP) and, if hindered, lead to glucose lowering, creating energy stress and deficiency [108] as shown in Figure 10.

Subsequently, Met has been shown to disrupt glucose homeostasis in cancer cells [109] by inhibiting complex I of the mitochondrial ETC and impairing ATP synthesis. This leads to energy deprivation and compromising vital cellular functions [110]. Firstly, due to a higher influx of Met in the presence of electric pulses, as shown in Figure 10, inhibition of complex I of the mitochondrial ETC decreases ATP production (from NADH) by preventing the transfer of electrons to subsequent complexes [111]. This decreases the proton gradient across the inner mitochondrial membrane, which is required for ATP synthesis. Subsequently, the increase in AMP and ADP combined with lower levels of ATP inhibits the enzymes needed for gluconeogenesis (a process generating glucose from non-carbohydrate sources).

Secondly, it increased ROS production. When complex I is inhibited by Met, electrons leak from the ETC to oxygen, forming ROS [112]. ROS imbalance can damage cellular components, such as DNA, proteins, and lipids, due to oxidative stress-mediated cell death pathways [113]. ROS include molecules like H₂O₂, which are generated as natural byproducts of cellular metabolism and essential proper functioning of living cells [114]. However, the experiment shows an upregulation (9.56-fold with respect to control) in ROS levels with Met treatment in the presence of EP. Prior studies show that Met has the ability to boost cell ROS levels [115], creating an imbalance between the production of ROS and the cell’s ability to detoxify them or repair the resulting damage [116]. ROS influence’s mitochondrial function, as excessive levels can damage mitochondrial components and impair oxidative phosphorylation, leading to altered energy production and cellular metabolism [117, 118].

Oxidative stress-mediated cell death pathways involve a complex interplay of genes and proteins responsible for cellular component damage [119, 120]. The tumor protein 53 (p53) is a prominent regulator, functioning as a transcription factor that governs the expression of genes involved in cell cycle arrest, apoptosis, and DNA repair [121]. Additionally, pro-apoptotic proteins such as B-cell lymphoma 2 (Bcl-2)-associated X protein (Bax) and Bcl-2 homologous antagonist killer (Bak) operate as effectors in the intrinsic apoptotic pathway, forming pores in the mitochondrial membrane, thereby facilitating the release of cytochrome c and triggering apoptosis [122]. All this evidence suggests that excessive ROS production with Met treatment in the presence of an electric field inhibits MDA-MB-231 cell growth due to oxidative stress.

Overall, the results indicate the impact of the various interventions, including electroporation, Met, and its combination, on cell viability, glucose, ROS, and cell migration in the MDA-MB-231 cells. The synergy of EP and Met is indicated a viability as low as 42.60% at 24 h for MDA-MB-231 cells. They also show the enhanced efficacy of Met in the presence of EP, disrupting glucose and ROS levels and hindering TNBC cell proliferation and survival. Thus, these studies lay a strong foundation for developing novel therapeutic approaches to treat TNBC patients using Met and contribute to the growing knowledge in TNBC research.

The limitations of this research include the use of in vitro model, under controlled laboratory conditions. This only mimic partially the true in vivo tumor microenvironment. However, the preliminary results provide the potential for several avenues of future research, such as the possibility of clinical translation (preclinical animal models and clinical trials) and the study of long-term effects, including developing potential resistance mechanisms.

Abbreviations

ADP

adenosine diphosphate

AMP

adenosine monophosphate

ANOVA

analysis of variance

ATP

adenosine triphosphate

BRCA1

breast cancer gene 1

confidence interval

electrical pulses

ETC

electron transport chain

HSD

honestly significant difference

Met

metformin

mTOR

mammalian target of rapamycin

not significantly

OCT

organic cation transporter

RLU

relative luminescence units

ROS

reactive oxygen species

TNBC

triple-negative breast cancer

Declarations Author contributions

PS: Conceptualization, Data curation, Formal analysis, Validation, Visualization, Writing—original draft, Writing—review & editing. IGC: Supervision, Methodology, Writing—review & editing. RS: Conceptualization, Supervision, Validation, Writing—review & editing. All authors read and approved the final manuscript.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

The raw data supporting the conclusions of this manuscript will be made available by the authors (Raji Sundararajan, raji@purdue.edu), without undue reservation, to any qualified researcher.

Funding

Not applicable.

Griffiths

Olin

Triple negative breast cancer: a brief review of its characteristics and treatment options

J Pharm Pract 2012 25 319 23

10.1177/0897190012442062

22551559

Kumar

Aggarwal

An overview of triple-negative breast cancer

Arch Gynecol Obstet 2016 293 247 69

10.1007/s00404-015-3859-y

26341644

Sonkar

Tressler

Glunde

Chemotherapeutic drugs profoundly alter the metabolism of triple negative breast cancer cells [Internet]

California: International Society for Magnetic Resonance in Medicine; 2023 [cited 2023 Jul 6]. Available from: https://cds.ismrm.org/protected/20MProceedings/PDFfiles/0126.html

National Breast Cancer Coalition [Internet]

Washington: The Association; c2023 [cited 2022 Oct 21]. Available from: https://www.stopbreastcancer.org/information-center/facts-figures/

Alshahrani

Alhammam

SYM

Munyif HAS

Alwadei

AMA

Alwadei

AMA

Alzamanan

SSM

et al.

Knowledge, attitudes, and practices of breast cancer screening methods among female patients in primary healthcare centers in Najran, Saudi Arabia

J Cancer Educ 2019 34 1167 72

10.1007/s13187-018-1423-8

30191519

PMC6882780

Sun

Zhao

Yang

Zhu

et al.

Risk factors and preventions of breast cancer

Int J Biol Sci 2017 13 1387 97

10.7150/ijbs.21635

29209143

PMC5715522

Sahu

Giri

Sunkara

Sundararajan

Extraction of key features and enhanced prediction framework of breast cancer occurrence

In: 2022 6th International Conference on Trends in Electronics and Informatics (ICOEI); 2022 April 28–30; Tirunelveli, India. New York: IEEE; 2022. pp. 1679–85.

10.1109/ICOEI53556.2022.9777165

Malmgren

Hurlbert

Atwood

Kaplan

Examination of a paradox: recurrent metastatic breast cancer incidence decline without improved distant disease survival: 1990–2011

Breast Cancer Res Treat 2019 174 505 14

10.1007/s10549-018-05090-y

30560462

PMC6422972

Caplan

Delay in breast cancer: implications for stage at diagnosis and survival

Front Public Health 2014 2

10.3389/fpubh.2014.00087

25121080

PMC4114209

Baranova

Krasnoselskyi

Starikov

Kartashov

Zhulkevych

Vlasenko

et al.

Triple-negative breast cancer: current treatment strategies and factors of negative prognosis

J Med Life 2022 15 153 61

10.25122/jml-2021-0108

35419095

PMC8999097

Fung

Zhu

RJY

Challenges and opportunities in metastatic breast cancer treatments: nano-drug combinations delivered preferentially to metastatic cells may enhance therapeutic response

Pharmacol Ther 2022 236

108108

10.1016/j.pharmthera.2022.108108

34999182

PMC9256851

Maqbool

Bekele

Fekadu

Treatment strategies against triple-negative breast cancer: an updated review

Breast Cancer: (Dove Med Press) 2022 14 15 24

10.2147/BCTT.S348060

35046722

PMC8760999

Uscanga-Perales

Santuario-Facio

Ortiz-López

Triple negative breast cancer: deciphering the biology and heterogeneity

Medicina Universitaria 2016 18 105 14

10.1016/j.rmu.2016.05.007

Shimelis

LaDuca

Hart

Thomas

et al.

Triple-negative breast cancer risk genes identified by multigene hereditary cancer panel testing

J Natl Cancer Inst 2018 110 855 62

10.1093/jnci/djy106

30099541

PMC6093350

Ellsworth

Turner

Ellsworth

A review of the hereditary component of triple negative breast cancer: high- and moderate-penetrance breast cancer genes, low-penetrance loci, and the role of nontraditional genetic elements

J Oncol 2019 2019

4382606

10.1155/2019/4382606

31379942

PMC6652078

Sharma

Klemp

Kimler

Mahnken

Geier

Khan

et al.

Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing

Breast Cancer Res Treat 2014 145 707 14

10.1007/s10549-014-2980-0

24807107

PMC4171847

Yin

Duan

Bian

Triple-negative breast cancer molecular subtyping and treatment progress

Breast Cancer Res 2020 22

10.1186/s13058-020-01296-5

32517735

PMC7285581

Doepker

Holt

Durkin

Chu

Nottingham

Triple-negative breast cancer: a comparison of race and survival

Am Surg 2018 84 881 8

29981619

Yeh

Chun

Schwartz

Wang

Kern

Guth

et al.

Clinical characteristics in patients with triple negative breast cancer

Int J Breast Cancer 2017 2017

1796145

10.1155/2017/1796145

28912973

PMC5585655

de Ruijter

Veeck

de Hoon

JPJ

van Engeland

Tjan-Heijnen

Characteristics of triple-negative breast cancer

J Cancer Res Clin Oncol 2011 137 183 92

10.1007/s00432-010-0957-x

21069385

PMC3018596

Mamidi

TKK

Zhang

Hicks

Unraveling the genomic-epigenomic interaction landscape in triple negative and non-triple negative breast cancer

Cancers (Basel) 2020 12

1559

10.3390/cancers12061559

32545594

PMC7352267

Chandran

Harmey

Toomey

Inhibition of IGF signalling pathway in MDA-MB-231 triple negative breast cancer cells

BMC Proc 2012 6

O14

10.1186/1753-6561-6-S4-O14

González-King

Tejedor

Ciria

Gil-Barrachina

Soriano-Navarro

Sánchez-Sánchez

et al.

Non-classical Notch signaling by MDA-MB-231 breast cancer cell-derived small extracellular vesicles promotes malignancy in poorly invasive MCF-7 cells

Cancer Gene Ther 2022 29 1056 69

10.1038/s41417-021-00411-8

35022518

Ehmsen

Ditzel

Signaling pathways essential for triple-negative breast cancer stem-like cells

Stem Cells 2021 39 133 43

10.1002/stem.3301

33211379

Costa

RLB

Han

Gradishar

Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review

Breast Cancer Res Treat 2018 169 397 406

10.1007/s10549-018-4697-y

29417298

Qin

Zang

Molecular mechanism of triple-negative breast cancer-associated BRCA1 and the identification of signaling pathways

Oncol Lett 2019 17 2905 14

10.3892/ol.2019.9884

30854067

PMC6365902

Khasawneh

Abu-El-Rub

Hypoxia disturbs the migration and adhesion characteristics of mesenchymal stem cells

Cell Mol Biol (Noisy-le-grand) 2022 68 28 32

10.14715/cmb/2022.68.11.5

37114312

Ismail-Khan

Bui

A review of triple-negative breast cancer

Cancer Control 2010 17 173 6

10.1177/107327481001700305

20664514

Dawood

Triple-negative breast cancer: epidemiology and management options

Drugs 2010 70 2247 58

10.2165/11538150-000000000-00000

21080741

Hosseini

Seyedpour

Khodaei

Loghman

Seyedpour

Yazdi

et al.

Cancer vaccines for triple-negative breast cancer: a systematic review

Vaccines (Basel) 2023 11

146

10.3390/vaccines11010146

36679991

PMC9866612

Rojas

LBA

Gomes

Metformin: an old but still the best treatment for type 2 diabetes

Diabetol Metab Syndr 2013 5

10.1186/1758-5996-5-6

23415113

PMC3607889

Babar

ZUD

Ramzan

El-Dahiyat

Tachmazidis

Adebisi

Hasan

The availability, pricing, and affordability of essential diabetes medicines in 17 low-, middle-, and high-income countries

Front Pharmacol 2019 10

1375

10.3389/fphar.2019.01375

31824316

PMC6880243

Aroda

Ratner

Metformin and type 2 diabetes prevention

Diabetes Spectr 2018 31 336 42

10.2337/ds18-0020

30510389

PMC6243218

Vancura

Bhagwat

Zeng

Vancurova

Metformin as an anticancer agent

Trends Pharmacol Sci 2018 39 867 78

10.1016/j.tips.2018.07.006

30150001

PMC6153060

Guo

Metformin and its benefits for various diseases

Front Endocrinol (Lausanne) 2020 11

191

10.3389/fendo.2020.00191

32425881

PMC7212476

Adak

Samadi

Ünal

Sabuncuoğlu

A reappraisal on metformin

Regul Toxicol Pharmacol 2018 92 324 32

10.1016/j.yrtph.2017.12.023

29291990

Madiraju

Erion

Rahimi

Zhang

Braddock

Albright

et al.

Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase

Nature 2014 510 542 6

10.1038/nature13270

24847880

PMC4074244

Hunter

Hughey

Lantier

Sundelin

Peggie

Zeqiraj

et al.

Metformin reduces liver glucose production by inhibition of fructose-1-6-bisphosphatase

Nat Med 2018 24 1395 406

10.1038/s41591-018-0159-7

30150719

PMC6207338

Lee

Kim

You

Moon

et al.

Metformin regulates glucose transporter 4 (GLUT4) translocation through AMP-activated protein kinase (AMPK)-mediated Cbl/CAP signaling in 3T3-L1 preadipocyte cells*

J Biol Chem 2012 287 44121 9

10.1074/jbc.M112.361386

23135276

PMC3531728

Herman

Kravos

Jensterle

Janež

Dolžan

Metformin and insulin resistance: a review of the underlying mechanisms behind changes in GLUT4-mediated glucose transport

Int J Mol Sci 2022 23

1264

10.3390/ijms23031264

35163187

PMC8836112

Yang

Holman

Long-term metformin treatment stimulates cardiomyocyte glucose transport through an AMP-activated protein kinase-dependent reduction in GLUT4 endocytosis

Endocrinology 2006 147 2728 36

10.1210/en.2005-1433

16513829

Hardie

AMPK: a target for drugs and natural products with effects on both diabetes and cancer

Diabetes 2013 62 2164 72

10.2337/db13-0368

23801715

PMC3712072

Bharath

Nikolajczyk

The intersection of metformin and inflammation

Am J Physiol Cell Physiol 2021 320 C873 9

10.1152/ajpcell.00604.2020

33689478

PMC8163577

Cameron

Morrison

Levin

Mohan

Forteath

Beall

et al.

Anti-inflammatory effects of metformin irrespective of diabetes status

Circ Res 2016 119 652 65

10.1161/CIRCRESAHA.116.308445

27418629

PMC4990459

Kasznicki

Sliwinska

Drzewoski

Metformin in cancer prevention and therapy

Ann Transl Med 2014 2

10.3978/j.issn.2305-5839.2014.06.01

25333032

PMC4200668

Saraei

Asadi

Kakar

Moradi-Kor

The beneficial effects of metformin on cancer prevention and therapy: a comprehensive review of recent advances

Cancer Manag Res 2019 11 3295 313

10.2147/CMAR.S200059

31114366

PMC6497052

Shi

Cai

Metformin and cancer: an existing drug for cancer prevention and therapy

Oncol Lett 2018 15 683 90

10.3892/ol.2017.7412

29422962

PMC5772929

Gao

Fang

Zhang

Metformin induces autophagy via the AMPK-mTOR signaling pathway in human hepatocellular carcinoma cells

Cancer Manag Res 2020 12 5803 11

10.2147/CMAR.S257966

32765083

PMC7371564

Hasanvand

The role of AMPK-dependent pathways in cellular and molecular mechanisms of metformin: a new perspective for treatment and prevention of diseases

Inflammopharmacol 2022 30 775 88

10.1007/s10787-022-00980-6

35419709

PMC9007580

Chomanicova

Gazova

Adamickova

Valaskova

Kyselovic

The role of AMPK/mTOR signaling pathway in anticancer activity of metformin

Physiol Res 2021 70 501 8

10.33549/physiolres.934618

34062070

PMC8820546

Weaver

Electroporation theory

Nickoloff

Plant cell electroporation and electrofusion protocols Methods in molecular biology™. Totowa

Springer

1995 pp. 3–28.

10.1385/0-89603-328-7:3

8528421

Weaver

Theory of electroporation

Martin

Blank

Igor

Vodyanoy

Biomembrane electrochemistry Washington

American Chemical Society

1994 pp. 447–70.

10.1007/978-0-387-79403-7_7

Gehl

Electroporation: theory and methods, perspectives for drug delivery, gene therapy and research

Acta Physiol Scand 2003 177 437 47

10.1046/j.1365-201X.2003.01093.x

12648161

Krassowska

Filev

Modeling electroporation in a single cell

Biophys J 2007 92 404 17

10.1529/biophysj.106.094235

17056739

PMC1751390

Joshi

Garner

Sundararajan

Review of developments in bioelectrics as an application of pulsed power technology

IEEE Trans Plasma Sci 2023 51 1682 717

10.1109/TPS.2023.3281339

Bolhassani

Khavari

Orafa

Electroporation-advantages and drawbacks for delivery of drug, gene and vaccine

Sezer

Application of nanotechnology in drug delivery London

IntechOpen

2014

10.5772/58376

Mittal

Raman

Camarillo

Sundararajan

Ultra-microsecond pulsed curcumin for effective treatment of triple negative breast cancers

Biochem Biophys Res Commun 2017 491 1015 20

10.1016/j.bbrc.2017.08.002

28780353

Rembiałkowska

Dubińska-Magiera

Sikora

Szlasa

Szewczyk

Czapor-Irzabek

et al.

Doxorubicin assisted by microsecond electroporation promotes irreparable morphological alternations in sensitive and resistant human breast adenocarcinoma cells

Appl Sci 2020 10

2765

10.3390/app10082765

Giri

Camarillo

Sundararajan

Enhancement of reactive oxygen species production in triple negative breast cancer cells treated with electric pulses and resveratrol

Explor Target Antitumor Ther 2023 4 42 56

10.37349/etat.2023.00122

36937321

PMC10017187

Sahu

Camarillo

Sundararajan

Enhanced antiproliferation potency of electrical pulse-mediated metformin and cisplatin combination therapy on MDA-MB-231 cells

Appl Biochem Biotechnol 2022 194 18 36

10.1007/s12010-021-03723-5

34741262

Giri

Camarillo

Sundararajan

Enhanced induction of MDA-MB-231 cell death using the combination of galloflavin and electroporation

Biointerface Res Appl Chem 2023 13

263

10.33263/BRIAC133.263

Cingir

Koker S

Yalcin

Dogan

Turacli I

Metformin resistant MDA-MB-468 cells exhibit EMT-like phenotype and increased migration capacity

Mol Biol Rep 2022 49 5973 84

10.1007/s11033-022-07381-6

35355210

Wang

Xie

Ren

Xia

Zhang

Establishment of a bioluminescent MDA-MB-231 cell line for human triple-negative breast cancer research

Oncol Rep 2012 27 1981 9

10.3892/or.2012.1742

22446691

Fani

Kamalidehghan

Nigjeh

Keong

Dehghan

et al.

Anticancer activity of a monobenzyltin complex C1 against MDA-MB-231 cells through induction of apoptosis and inhibition of breast cancer stem cells

Sci Rep 2016 6

38992

10.1038/srep38992

27976692

PMC5157033

Huang

Tang

Characterization of triple-negative breast cancer MDA-MB-231 cell spheroid model

Onco Targets Ther 2020 13 5395 405

10.2147/OTT.S249756

32606757

PMC7295545

Kim

Langley

Fidler

Modulation of the cancer cell transcriptome by culture media formulations and cell density

Int J Oncol 2015 46 2067 75

10.3892/ijo.2015.2930

25776572

PMC4383016

Drug Approval Package [Internet]

Silver Spring: U.S. Food and Drug Administration; [cited 2022 Nov 8]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/020357s010.cfm

Bharatam

Patel

Iqbal

Pharmacophoric features of biguanide derivatives: an electronic and structural analysis

J Med Chem 2005 48 7615 22

10.1021/jm050602z

16302801

Campbell

White

Saulie

Metformin: a new oral biguanide

Clin Ther 1996 18 360 71

10.1016/s0149-2918(96)80017-8

8829014

Magno L

Pastena F

Bordone

Coni

Canettieri

The mechanism of action of biguanides: new answers to a complex question

Cancers (Basel) 2022 14

3220

10.3390/cancers14133220

35804992

PMC9265089

Biguanide derivative [Internet]

Amsterdam: Elsevier; c2023 [cited 2023 Jun 19]. Available from: https://www.sciencedirect.com/topics/medicine-and-dentistry/biguanide-derivative

Klepser

Kelly

Metformin hydrochloride: an antihyperglycemic agent

Am J Health Syst Pharm 1997 54 893 903

10.1093/ajhp/54.8.893

9114921

Hariharan

Rajan

Srinivasan

Structure of metformin hydrochloride

Acta Cryst C 1989 45 911 3

10.1107/S0108270188014246

Benmessaoud

Koutchoukali

Bouhelassa

Nouar

Veesler

Solvent screening and crystal habit of metformin hydrochloride

J Cryst Growth 2016 451 42 51

10.1016/j.jcrysgro.2016.07.001

Diabetes Prevention Program Research Group

Long-term safety, tolerability, and weight loss associated with metformin in the diabetes prevention program outcomes study

Diabetes Care 2012 35 731 7

10.2337/dc11-1299

22442396

PMC3308305

ChemSpider [Internet]

London: Royal Society of Chemistry; c2023 [cited 2023 Jul 6]. Available from: https://www.chemspider.com/

Wang

Yang

Wen

Chen

Liang

et al.

Rapid and high efficiency transformation of Chlamydomonas reinhardtii by square-wave electroporation

Biosci Rep 2019 39

BSR20181210

10.1042/BSR20181210

30530569

PMC6328877

RealTime-Glo™ MT cell viability assay [Internet]

Madison; Promega Corporation; c2014-2021 [cited 2022 Nov 8]. Available from: https://www.promega.com/-/media/files/resources/protocols/technical-manuals/101/realtimeglo-mt-cell-viability-assay-protocol.pdf?rev=63ece8344f0647d1a028b59c1952dfe4&sc_lang=en

Kumar

Srivastava

Detection and classification of cancer from microscopic biopsy images using clinically significant and biologically interpretable features

J Med Eng 2015 2015

457906

10.1155/2015/457906

27006938

PMC4782618

Valley

Karassina

Aoyama

Carlson

Cali

Vidugiriene

A bioluminescent assay for measuring glucose uptake

Anal Biochem 2016 505 43 50

10.1016/j.ab.2016.04.010

27130501

Kelts

Cali

Duellman

Shultz

Altered cytotoxicity of ROS-inducing compounds by sodium pyruvate in cell culture medium depends on the location of ROS generation

Springerplus 2015 4

269

10.1186/s40064-015-1063-y

26090316

PMC4469600

Wang

Decker

Zechner

Krstin

Wink

In vitro wound healing of tumor cells: inhibition of cell migration by selected cytotoxic alkaloids

BMC Pharmacol Toxicol 2019 20

10.1186/s40360-018-0284-4

30626448

PMC6327619

Suh

Robinson

Zanghi

Kratz

Gustetic

Crow

et al.

Introducing wound healing assays in the undergraduate biology laboratory using Ibidi plates

J Microbiol Biol Educ 2022 23

e00061-22

10.1128/jmbe.00061-22

36061326

PMC9429954

Suarez-Arnedo

Figueroa

Clavijo

Arbeláez

Cruz

Muñoz-Camargo

An image J plugin for the high throughput image analysis of in vitro scratch wound healing assays

PLoS One 2020 15

e0232565

10.1371/journal.pone.0232565

32722676

PMC7386569

Lee

What is the proper way to apply the multiple comparison test?

Korean J Anesthesiol 2018 71 353 60 Erratum in: Korean J Anesthesiol. 2020;73:572.

10.4097/kja.d.18.00242

30157585

PMC6193594

McHugh

Multiple comparison analysis testing in ANOVA

Biochem Med 2011 21 203 9

10.11613/bm.2011.029

22420233

Deng

Schoenbach

Buescher

Hair

Fox

Beebe

The effects of intense submicrosecond electrical pulses on cells

Biophys J 2003 84 2709 14

10.1016/s0006-3495(03)75076-0

12668479

PMC1302837

Viollet

Guigas

Sanz

Garcia N

Leclerc

Foretz

Andreelli

Cellular and molecular mechanisms of metformin: an overview

Clin Sci (Lond) 2012 122 253 70

10.1042/CS20110386

22117616

PMC3398862

Mukherjee

Nathamgari

SSP

Kessler

Espinosa

Combined numerical and experimental investigation of localized electroporation-based cell transfection and sampling

ACS Nano 2018 12 12118 28

10.1021/acsnano.8b05473

30452236

PMC6535396

Probst

Fuhrmann

Beyer

Wiggermann

Electrochemotherapy as a new modality in interventional oncology: a review

Technol Cancer Res Treat 2018 17

1533033818785329

10.1177/1533033818785329

29986632

PMC6048674

Shinoda

Matsuzaki

Yokoo-Sugawara

Suzuki

Aoki

Hagiwara

et al.

Introduction and expression of glucose transporters in pancreatic acinar cells by in vivo electroporation

Acta Histochem Cytochem 2003 36 77 82

Scuderi

Dermol-Černe

Amaral

da Silva C

Muralidharan

Boukany

Rems

Models of electroporation and the associated transmembrane molecular transport should be revisited

Bioelectrochemistry 2022 147

108216

10.1016/j.bioelechem.2022.108216

35932533

Alberts

Johnson

Lewis

Raff

Roberts

Walter

Looking at the structure of cells in the microscope Molecular biology of the cell 4th edition. New York

Garland Science

2002

Mahmoud

Cougnoux

Bekiari

Araceli

Ruiz de Castroviejo Teba P

Marrahi A

Panneau

et al.

Microscopy-based phenotypic monitoring of MDA-MB-231 spheroids allows the evaluation of phenotype-directed therapy

Exp Cell Res 2023 425

113527

10.1016/j.yexcr.2023.113527

36889574

Jonkman

JEN

Cathcart

Bartolini

Amon

Stevens

et al.

An introduction to the wound healing assay using live-cell microscopy

Cell Adh Migr 2014 8 440 51

10.4161/cam.36224

25482647

PMC5154238

Bravo-Cordero

Hodgson

Condeelis

Directed cell invasion and migration during metastasis

Curr Opin Cell Biol 2012 24 277 83

10.1016/j.ceb.2011.12.004

22209238

PMC3320684

Bahar

Yoon

Modeling and predicting the cell migration properties from scratch wound healing assay on cisplatin-resistant ovarian cancer cell lines using artificial neural network

Healthcare (Basel) 2021 9

911

10.3390/healthcare9070911

34356289

PMC8305856

Lord

Harris

Is it still worth pursuing the repurposing of metformin as a cancer therapeutic?

Br J Cancer 2023 128 958 66

10.1038/s41416-023-02204-2

36823364

PMC10006178

Wang

Tahiri

Yang

Ruan

Hardy

Overexpression of miR-181a regulates the Warburg effect in triple-negative breast cancer

Climacteric 2023 26 64 71

10.1080/13697137.2022.2147821

36459490

100

Shin

Koo

Glucose metabolism and glucose transporters in breast cancer

Front Cell Dev Biol 2021 9

728759

10.3389/fcell.2021.728759

34552932

PMC8450384

101

Barbosa

Martel

Targeting glucose transporters for breast cancer therapy: the effect of natural and synthetic compounds

Cancers (Basel) 2020 12

154

10.3390/cancers12010154

31936350

PMC7016663

102

Ganapathy-Kanniappan

Geschwind

JFH

Tumor glycolysis as a target for cancer therapy: progress and prospects

Mol Cancer 2013 12

152

10.1186/1476-4598-12-152

24298908

PMC4223729

103

Choi

Kim

Homeostatic regulation of glucose metabolism by the central nervous system

Endocrinol Metab (Seoul) 2022 37 9 25

10.3803/EnM.2021.1364

35255598

PMC8901968

104

Sun

Chen

Xue

The role of GLUT2 in glucose metabolism in multiple organs and tissues

Mol Biol Rep 2023 50 6963 74

10.1007/s11033-023-08535-w

37358764

PMC10374759

105

Post-genomic analysis of fatty acid and glucose metabolism in cardiovascular disease In

Marín-García J

Post-genomic eardiology (second edition). Boston

Academic Press

2014 pp. 533–59.

106

Cooper

The mechanism of oxidative phosphorylation The cell

a molecular approach 2nd edition. Sunderland: Sinauer Associates

2000

107

Froissart

Piraud

Boudjemline

Vianey-Saban

Petit

Hubert-Buron

et al.

Glucose-6-phosphatase deficiency

Orphanet J Rare Dis 2011 6

10.1186/1750-1172-6-27

21599942

PMC3118311

108

Shiratori

Furuichi

Yamaguchi

Miyazaki

Aoki

Chibana

et al.

Glycolytic suppression dramatically changes the intracellular metabolic profile of multiple cancer cell lines in a mitochondrial metabolism-dependent manner

Sci Rep 2019 9

18699

10.1038/s41598-019-55296-3

31822748

PMC6904735

109

Guo

Yang

Liao

Shen

et al.

Metformin targets foxo1 to control glucose homeostasis

Biomolecules 2021 11

873

10.3390/biom11060873

34208360

PMC8231152

110

Wheaton

Weinberg

Hamanaka

Soberanes

Sullivan

Anso

et al.

Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis

Elife 2014 3

e02242

10.7554/eLife.02242

24843020

PMC4017650

111

Zhao

Jiang

Zhang

Mitochondrial electron transport chain, ROS generation and uncoupling (Review)

Int J Mol Med 2019 44 3 15

10.3892/ijmm.2019.4188

31115493

PMC6559295

112

Pizzino

Irrera

Cucinotta

Pallio

Mannino

Arcoraci

et al.

Oxidative stress: harms and benefits for human health

Oxid Med Cell Longev 2017 2017

8416763

10.1155/2017/8416763

28819546

PMC5551541

113

Cheung

Vousden

The role of ROS in tumour development and progression

Nat Rev Cancer 2022 22 280 97

10.1038/s41568-021-00435-0

35102280

114

Liou

Storz

Reactive oxygen species in cancer

Free Radic Res 2010 44 479 96

10.3109/10715761003667554

20370557

PMC3880197

115

Diniz

Vilela D

Gomes

Peixoto L

Teixeira

Belele

Baptista N

Carvalho

Caixeta D

Vieira

de Souza A

et al.

The role of metformin in controlling oxidative stress in muscle of diabetic rats

Oxid Med Cell Longev 2016 2016

6978625

10.1155/2016/6978625

27579154

PMC4989083

116

D’Autréaux

Toledano

ROS as signalling molecules: mechanisms that generate specificity in ROS homeostasis

Nat Rev Mol Cell Biol 2007 8 813 24

10.1038/nrm2256

17848967

117

Zorov

Juhaszova

Sollott

Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS release

Physiol Rev 2014 94 909 50

10.1152/physrev.00026.2013

24987008

PMC4101632

118

Guo

Sun

Chen

Zhang

Oxidative stress, mitochondrial damage and neurodegenerative diseases

Neural Regen Res 2013 8 2003 14

10.3969/j.issn.1673-5374.2013.21.009

25206509

PMC4145906

119

Rowe

Degtyareva

Doetsch

DNA damage-induced reactive oxygen species (ROS) stress response in Saccharomyces cerevisiae

Free Radic Biol Med 2008 45 1167 77

10.1016/j.freeradbiomed.2008.07.018

18708137

PMC2643028

120

Auten

Davis

Oxygen toxicity and reactive oxygen species: the devil is in the details

Pediatr Res 2009 66 121 7

10.1203/PDR.0b013e3181a9eafb

19390491

121

Hamzehloie

Mojarrad

Hasanzadeh_Nazarabadi

Shekouhi

The role of tumor protein 53 mutations in common human cancers and targeting the murine double minute 2–P53 interaction for cancer therapy

Iran J Med Sci 2012 37 3 8

23115424

PMC3470295

122

Peña-Blanco

García-Sáez

Bax, Bak and beyond – mitochondrial performance in apoptosis

FEBS J 2018 285 416 31

10.1111/febs.14186

28755482